中国生物制药（01177）今日盘中股价大幅上涨5.08%，引起了市场的广泛关注。
消息面上，公司宣布其附属公司正大天晴与赛诺菲就全球首创口服小分子JAK/ROCK双靶点抑制剂罗伐昔替尼（商品名：安煦）订立了独家授权协议。根据协议，中国生物制药将获得1.35亿美元的首付款、最高可达13.95亿美元的里程碑付款，并享有基于该药物年度净销售额的最高双位数阶梯式特许权使用费。
此次授权标志着中国生物制药在创新药全球化布局上取得重大突破，市场预期该交易将显著增厚公司未来多年的收入与利润，并强化其在血液肿瘤及免疫纤维化领域的国际竞争力，从而推动了股价的积极表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.